Tobracid Dm 3 Gm

説明

Tobracid Dm 3 Gm Tablets (Tobramycin 0.3% & Dexamethasone 0.1% w/w Ophthalmic Ointment): Clinical Profile, Uses, Dosage, and Safety

Tobracid Dm 3 Gm Tablets is a prescription product containing Tobramycin 0.3% & Dexamethasone 0.1% w/w Ophthalmic Ointment. It is used in clinically selected treatment pathways and should be used only under professional supervision. This page summarizes core product facts to support informed discussions with licensed healthcare professionals.

Safe use depends on diagnosis, formulation, route, dose, and duration. For this reason, the sections below provide a structured profile aligned with clinical documentation standards for pharmaceutical education.

Introduction

Tobracid Dm 3 Gm Tablets is a ophthalmic solution manufactured by Entod Pharmaceuticals Ltd . Specifically designed for the management of steroid-r. It is commonly positioned within the antibiotic class and is typically prescribed for clearly defined therapeutic use cases. While product names are familiar to patients, treatment decisions should always be guided by clinical evaluation and official labeling.

Patients should verify product identity, strength, and route every time a medicine is dispensed. Similar-looking brand names can represent different active ingredients, and substitutions should only be made with clinician or pharmacist confirmation.

1. Product Overview / Clinical Profile

• Brand Name: Tobracid Dm 3 Gm Tablets
• Active Ingredient: Tobramycin 0.3% & Dexamethasone 0.1% w/w Ophthalmic Ointment
• Manufacturer: Entod Pharmaceuticals Ltd . Specifically designed for the management of steroid-r
• Dosage Form: ophthalmic solution
• Therapeutic Category: antibiotic

2. Mechanism of Action (MOA)

Tobracid Dm 3 Gm Tablets acts through Tobramycin 0.3% & Dexamethasone 0.1% w/w Ophthalmic Ointment, an antibacterial mechanism that inhibits critical microbial growth pathways and supports clearance of susceptible infections when used at the prescribed dose and duration.

Mechanistic understanding helps explain prescribing rationale, expected response timelines, and monitoring requirements. For antimicrobials, susceptibility patterns and resistance risk are central. For ocular pressure therapies, durable adherence and pressure control trends matter more than short-term symptom fluctuations. For anti-inflammatory and other chronic-use medicines, risk-benefit is reassessed through follow-up.

MOA should always be interpreted in context: pharmacology defines potential effect, but real-world response depends on diagnosis quality, adherence, interacting medicines, and patient-specific comorbid conditions.

3. Therapeutic Indications

Tobracid Dm 3 Gm Tablets is typically used for bacterial conjunctivitis and related susceptible ocular infections. Final indication should match local labeling, clinician judgement, and patient-specific risk profile.

• Use only for the indication selected by a licensed prescriber.
• Avoid self-initiating or extending treatment duration without clinical review.
• Reassessment is needed if expected improvement does not occur.

Clinical teams often adjust treatment based on severity, prior therapy exposure, and response monitoring. The objective is to achieve therapeutic benefit while minimizing avoidable adverse events.

4. Dosage and Administration

General dosing guidance: 3 mg (0, or as directed by the prescriber.

Exact schedules vary by diagnosis and patient profile. Prescribed instructions on label frequency, duration, and technique should be followed precisely.

• Use exactly as directed by the prescriber.
• Do not skip doses or double up missed doses unless advised.
• If ophthalmic, avoid touching the dropper/tube tip to any surface.
• If injectable, follow sterile handling and storage requirements.
• Ask the clinician for written missed-dose guidance at initiation.

Administration quality can materially affect outcomes. Correct timing, route, and storage are often as important as selecting the correct medicine class.

5. Safety Profile and Precautions

副作用のプロファイルは、有効成分や薬剤クラスによって異なります。患者は、使用前に禁忌事項、アレルギー歴、臓器機能上の懸念事項、相互作用リスクを確認する必要があります。持続的、重度、または予期しない症状がある場合は、速やかに医療機関に相談してください。

重要な注意事項には、処方された期間に従うこと、医師の指導なしに用量を増加させないこと、および効果不足の場合は早期に報告することが含まれます。眼科製剤の場合、衛生管理と汚染防止が特に重要です。全身性薬剤の場合、リスク因子に応じて臨床医は検査を要することがあります。

重度の過敏症反応、呼吸困難、徐々に進行する腫れ、急激な視力変化、またはその他の急性悪化の兆候がある場合は、直ちに緊急医療を求めてください。

保管と取り扱い

製品ラベルに従って保管してください。薬品は元の容器に入れたまま、熱や湿気のない場所に保管し、子供の手の届かない場所に置いてください。眼科製剤は常にキャップを閉め、汚染を防ぎます。注射剤は厳格な温度管理が必要な場合があります。

期限切れまたは損傷した製品は使用しないでください。容器に損傷がある場合は、薬剤師または医療従事者が適切な使用可否を確認するまで使用を延期してください。

臨床フォローアップとカウンセリングポイント

フォローアップでは、臨床的な反応、耐容性、服薬遵守状況を評価します。患者には、薬剤リストを保持し、市販薬の使用を報告し、治療変更を医療機関間で共有するよう促してください。カウンセリングでは、本情報は教育目的であり、個別診断に代わるものではないことを強調してください。

必要に応じて、医療従事者は地域の抗菌薬管理、慢性疾患プロトコル、または専門分野の経路に沿って治療を調整し、効果を維持し、回避可能なリスクを低減します。